ReviewFrontiers in immunology2024
Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study.Transplantation and cellular therapy · 2026Trial
- Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up.Translational cancer research · 2026Article
- Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States.Future oncology (London, England) · 2026Article
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
- Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice.Frontiers in oncology · 2026Article
- Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.Future oncology (London, England) · 2025Review
- Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.European journal of haematology · 2025Review
- Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for hematological malignancies, showing high efficacy in patients with relapsed or refractory (R/R) disease and otherwise poor prognosis in the pre-CAR-T era. These therapies have been usually administered in the inpatient setting due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). However, there is a growing interest in the transition to outpatient administration due to multiple reasons. We review available evidence regarding safety and feasibility of outpatient administration of CD19 targeted and BCMA targeted CAR T-cell therapy with an emphasis on the implementation of outpatient CAR-T programs in community-based centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.